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Bone-derived microglia clear amyloid plaques  
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Alzheimer’s disease (AD) is an incurable 
neurodegenerative disease and is the most common 
cause of dementia that affects elderly people (Izenberg, 
2000). Today as citizens are living longer, AD is 
reaching epidemic proportions with no cure available 
(Tanzi and Bertram, 2005). In America, 4 million people 
are affected by this disease and it is estimated that the 
epidemic will jump 44 percent by the year of 2025 
(Medline Plus, 2006). AD patients live debilitating lives 
of faulty memory, judgment, and reasoning (Tanzi and 
Bertram, 2005). However, a promising study published 
in Neuron by Simard et al. (2006) suggests a future 
therapeutic strategy. They employ stem cells that 
specifically target the amyloid deposits, the toxic culprit 
in this disease pathology.     
When Alzheimer’s disease strikes the brain, it 
makes three main aberrant structural changes. One 
change is the extensive loss of neurons in the 
hippocampus and neocortex. The second change is the 
accumulation of intracellular protein deposits called 
neurofibrillary tangles. The third change is the 
accumulation of extracellular protein deposits termed 
amyloid (Αβ , also called senile plaques, surrounded by 
damaged neurites (George-Hyslop and Westaway, 
1999). 
The build up of Aβ in the brain is considered to be 
a major cause toward AD pathogenesis. Aβ is naturally 
produced by the breakdown of a bigger protein called β-
amyloid precursor protein (APP). However, in AD 
patients, the problem occurs when the APP is mutant. 
The mutation progresses the production of too much Aβ 
(Hardy and Selkoe, 2002).  
Thus far, the research on amyloid plaques has 
shown that they influence significant immunological 
changes in their cellular environment. When Aβ 
deposits build up, they elicit an innate immune 
response on the central nervous system (CNS) 
(Monsonego and Weiner, 2003). Specifically, they 
activate the microglia, which are the immune cells of 
brain. The inflammatory response triggers the microglia 
to surround the amyloid deposits. This behavior of 
microglia immune cells has been observed in the rodent 
transgenic model of AD (Malm et al., 2005).  
Interestingly, the scientific community is in a 
debate over the role of microglia in Alzheimer’s 
Disease. Since there is a large amount of microglia in 
the diseased brain, they must, undisputably, play an 
important pathological role. (Rogers et al., 2002).  
Studies show activated brain microglia to have the 
capacity to be either potentially neurotoxic or beneficial 
to the brain. In test tube studies, when cultured 
microglial cells encounter Aβ peptides  they trigger an 
immune response and secrete high levels of 
proinflammatory cytokines. However, the secretion of 
cytokines in the brain would be fatal. (Rogers et al., 
2002). On the other hand, test tube studies also show 
that the microglial cells play a positive role. They clear 
up cellular debris and certainly are capable of clearing 
Aβ  deposits  by phagocytosis (Wegiel et al., 2004).   
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Nevertheless, studying the role of microglia in AD 
animal model is more relevant than any study in the test 
tube. In AD mouse model, the outcome of clearing Aβ  
deposits by microglia has been questionable because 
Aβ  deposits are abundant in the brain and form faster 
than they can be cleared by the microglia (Wegiel et al., 
2004). Prior to the research done by Simard et al. 
(2006), the microglia have been shown to be inefficient 
at degrading Aβ deposits.  
Now, in the study of AD using transgenic mice 
model, Simard et al. (2006) show that there are other 
efficient microglia of blood origin which specifically 
phagocytose amyloid plaques. Simard and colleagues 
demonstrate that the monocytes pass through the blood 
brain barrier of CNS and differentiate into microglia. 
These blood-derived microglia are shown to closely 
associate with Aβ deposits. In the AD affected region of 
the hippocampus, Simard et al. found bone marrow-
derived miroglia to colocalize with the β-amyloid 40/42.   
Following the first evidence, Simard et al. (2006) 
test a very important question of whether blood-derived 
microglia are beneficial in slowing down the build up of 
amyloid plaques. They treat the undifferentiated blood 
derived cells with ganciclovir drug that impedes the 
cells differentiation into microglia.  The scientists closely 
observe the changes in Aβ formation strictly when no 
blood-derive microglia are created. They discover that 
the size and the number of amyloid plaques increase 
with ganciclovir treatment.    
In addition, they see a second type of non-blood 
derived (resident) microglia associate with Aβ  deposits 
but unlike the blood microglia, they are not able to clear 
amyloid plaques. This observation seriously suggests 
that the blood-derived microglia are specific species of 
the brain immune cells better capable of removing the 
amyloid plaques and possibly further preventing the 
plaque formations. 
Simard et al. (2006) observe that as Aβ deposits 
associate with bone marrow-derived microglia, an 
immune response is elicited. Astonishingly, this 
response happens to be concurrent with the decrease 
in the size and the number of amyloid plaques. As 
such, blood-derived microglia draws a beneficial 
mechanism. It is a converse of the response that 
resident microglia produce in which dangerous 
proinflammatory cytokines secrete.   
Past in vivo experiments have shown that resident 
and blood-derived microglial cells are not distinguished 
in their function.  Usually, these studies comment on 
the idea that microglia are incapable of phagocytosing 
amyloid plaques.  However, Simard et al. (2006) make 
an attempt to clear up the confusion that exists in 
explaining the role of microglia. There are two types of 
microglia: resident microglia and blood-derived 
microglia. The latter perform a beneficial mechanism for 
the cell by carrying out phagocytosis and protecting the 
central nervous system from a neurodegenerative 
disease. 
In the last decade, therapeutic methods of 
preventing and curing AD have failed. In the Simard et 
al. (2006) study, the bone marrow stem cells shine on a 
novel strategy of eliminating amyloid plaques to 
possibly treat AD patients (Figure 1). There is a strong 
belief now that the prospect of treating Alzheimer’s 
Disease will come from learning more about how the 
immune response plays a role in the degenerative 
process (Monsonego and Weiner, 2003).  
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Since the activation of blood-derived microglial 
cells create an immune response which reduces the 
size and the number of amyloid plaques, these 
microglial cells may be the key for AD therapy.  
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Figure 1: Blood-derived microglia specifically target amyloid plaques for elimination by phagocytosis. 
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